Is compounded semaglutide still legal in 2026?
Written by
WeighedHealth Editorial Team
Editorial team-reviewed
Against primary clinical sources- Apr 0 2026
- FDA 503B bulks-list proposal
- 0
- FDA warning letters, March 2026
- Mar 0 2026
- Hims shifts to branded GLP-1
- Jul 0 2026
- FDA comment period closed
For two years, compounded semaglutide was the affordable on-ramp to GLP-1 weight loss. A drug shortage gave compounding pharmacies legal cover to produce it at scale, and telehealth platforms built entire businesses on the price gap between compounded versions and branded pens (Wegovy's list price is $1,349.02 per package). That era is ending.
The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage in February 2025. In March 2026 it sent 30 warning letters to telehealth firms marketing compounded GLP-1s. On April 30, 2026, it proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list (91 FR 23431), finding no clinical need for outsourcing facilities to compound these drugs from bulk substances. The comment period was extended to July 30, 2026; no final determination had been published as of September 2026.
If the proposal is finalized, outsourcing facilities could not compound these drugs from bulk substances unless they return to the FDA shortage list. The largest platform has already changed course: on March 9, 2026 Hims & Hers stopped advertising compounded GLP-1s after Novo Nordisk dismissed its lawsuit and the two companies announced a partnership. Hims still offers compounded semaglutide in limited cases where a provider documents clinical need.
Frequently asked questions
- Is compounded semaglutide legal right now (September 2026)?
- It exists in a narrowing legal grey zone. The FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025, and the compounding grace periods ended by May 22, 2025. In March 2026 the FDA sent 30 warning letters to telehealth firms marketing compounded GLP-1s. On April 30, 2026 the FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list (91 FR 23431); the comment period was extended to July 30, 2026, and no final determination had been published as of September 2026. Compounding for genuine individual clinical needs (documented allergy to an inactive ingredient, a dose not commercially made) may still be permitted under 503A, but routine 'cheaper alternative' compounding is being shut down.
- What happens to my prescription if the FDA finalizes the proposal?
- Outsourcing facilities (503B) could not compound semaglutide, tirzepatide, or liraglutide from bulk substances unless the drug returns to the FDA shortage list. Most patients would need to transition to branded Wegovy, Ozempic, Zepbound, or Mounjaro, or to a manufacturer direct-pay channel (NovoCare, LillyDirect). The comment period closed July 30, 2026 and no final determination had been published as of September 2026, so plan the transition with your prescriber now.
- Did Hims stop selling compounded semaglutide?
- Partly. On March 9, 2026, Hims & Hers said it would stop advertising compounded GLP-1s and move existing patients to FDA-approved medicines where clinically appropriate. The same day Novo Nordisk dismissed its lawsuit against Hims without prejudice, and the companies announced a partnership that brings Wegovy and Ozempic to the platform. Hims still offers compounded semaglutide in limited cases where a provider determines it is clinically necessary.
- Is compounded semaglutide safe?
- Compounded drugs do not undergo FDA review for safety, efficacy, or manufacturing quality. Quality varies by pharmacy. The FDA has documented dosing errors and contamination concerns in some compounded GLP-1 products. If you use a compounded version, confirm the dispensing pharmacy is 503A or 503B registered and ask which facility produces the compound.
- What are my cheaper options if compounded goes away?
- Manufacturer direct-pay channels narrowed the gap: NovoCare self-pay Wegovy is $349/month (new patients pay $199/month for the first two fills of 0.25 mg and 0.5 mg, through December 31, 2026) and LillyDirect Zepbound vials are $299-449/month by dose. The oral options cost less at low doses: the Wegovy pill is $149-299/month via NovoCare Pharmacy and Foundayo (orforglipron) is $149-299/month via LillyDirect. Insurance with prior authorization remains the cheapest path when available.
Your options as compounding ends
Primary sources: FDA 503B bulks-list proposal, Federal Register comment-period extension, FDA warning letters (March 2026), FDA shortage resolution, Hims & Hers (March 9, 2026), Wegovy list price (NovoCare).